Clinical Trials of Oncolytic Viruses in Breast Cancer

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Breast cancer is a leading global cancer. Oncolytic virotherapy presents a novel therapeutic strategy.
• Oncolytic viruses are engineered or naturally occurring viruses that selectively infect and kill cancer cells, while sparing normal cells.
• Three main categories of oncolytic viruses are utilized in clinical settings: naturally anti-neoplastic, tumor-selective replicating, and immune-activating modified viruses.

Purpose of the Study:

• To review the current landscape of oncolytic virus clinical trials for cancer treatment.
• To assess the safety, tolerability, and clinical activity of oncolytic viruses.
• To identify future research directions for optimizing oncolytic virotherapy in breast cancer.

Main Methods:

• Systematic review of published clinical trials involving oncolytic viruses.
• Analysis of data from eighteen clinical trials investigating fourteen different oncolytic viruses.
• Focus on patient populations, tumor types, safety profiles, and observed clinical activity.

Main Results:

• Oncolytic viruses have been investigated in eighteen clinical trials involving fourteen distinct agents.
• These trials indicate that oncolytic viruses are generally well-tolerated and safe in patients.
• Clinical activity has been observed, although trials often included small numbers of patients with diverse advanced tumors, including breast cancer.

Conclusions:

• Oncolytic virotherapy is a safe and potentially active treatment modality for cancer.
• Further clinical trials specifically focused on breast cancer are warranted.
• Future research should explore optimal administration routes, immunogenicity, viral gene expression, combination therapies, and patient stratification for breast cancer oncolytic virotherapy.